CDK4
ENSG00000135446
Target class
Kinase
Chromosome
12
Approved drugs
6
Clinical candidates (approved and in development)
18
- Approved drugs
- 6
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 18
- Chemical probe available
- Yes
- Other names
- PSK-J3
- Target name
- CDK4
- Gene name
- Cyclin dependent kinase 4
- Gene symbol
- CDK4
- Protein name
- Cyclin-dependent kinase 4 (EC 2.7.11.22) (Cell division protein kinase 4) (PSK-J3)
- Gene biotype
- Protein coding
- Gene family
- Cyclin dependent kinases|MicroRNA protein coding host genes
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 154.33
- Tissue specificity (Gini)
- 0.358
- Tissue specificity (tau)
- 0.694
- KEGG gene identifiers
- hsa:1019
- Protein interaction confidence
- 0.835556
- Protein interaction partners
- 124
- R-HSA-187577
- R-HSA-2559580
- R-HSA-2559582
- R-HSA-2559585
- R-HSA-3214858
- R-HSA-381340
- R-HSA-69231
- R-HSA-75815
- R-HSA-8849470
- R-HSA-8878166
- R-HSA-912446
- R-HSA-9616222
- R-HSA-9630791
- R-HSA-9630794
- R-HSA-9632697
- R-HSA-9632700
- R-HSA-9661069
- R-HSA-9754119
- R-HSA-9929491
- End position
- 57756013
- Start position
- 57747722
- Chromosome
- 12
- Strand
- Reverse
- Cytoplasm . Nucleus . Nucleus membrane . Note=Cytoplasmic when non-complexed. Forms a cyclin D-CDK4 complex in the cytoplasm as cells progress through G(1) phase. The complex accumulates on the nuclear membrane and enters the nucleus on transition from G(1) to S phase. Also present in nucleoli and heterochromatin lumps. Colocalizes with RB1 after release into the nucleus. .
- Cytosol
- Nuclear membrane
- Nucleoli
- Nucleoplasm
- PubMed 18827403
- PubMed 20399237
- PubMed 9106657
- Tissue specificity (tau)
- 0.693597
- Expression inequality (Gini)
- 0.358463
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 154.33
- Cells - EBV-transformed lymphocytes
- 141.2
- Ovary
- 113.27
- Uterus
- 107.81
- Cervix - Endocervix
- 101
Expression in transcripts per million
- Cells - Cultured fibroblasts154.33
- Cells - EBV-transformed lymphocytes141.2
- Ovary113.27
- Uterus107.81
- Cervix - Endocervix101
- Cervix - Ectocervix97.23
- Fallopian Tube85.15
- Adrenal Gland74.74
- Nerve - Tibial73.93
- Bladder69.41
- Vagina68.11
- Thyroid66.97
- Pituitary66.06
- Breast - Mammary Tissue65.71
- Adipose - Subcutaneous65.39
- Adipose - Visceral (Omentum)63.63
- Artery - Aorta61.88
- Lung60.44
- Artery - Coronary60.3
- Artery - Tibial59.61
- Colon - Sigmoid55.93
- Skin - Sun Exposed (Lower leg)54.28
- Prostate53.25
- Skin - Not Sun Exposed (Suprapubic)52.04
- Esophagus - Gastroesophageal Junction51.36
And 29 more, listed on the interactive page.
- GO:0000082
- GO:0008284
- GO:0009410
- GO:0010468
- GO:0010971
- GO:0048146
- GO:0051726
- GO:0060260
- GO:0000307
- GO:0000785
- GO:0005634
- GO:0005654
- GO:0005730
- GO:0005737
- GO:0005829
- GO:0031965
- GO:0004693
- GO:0005515
- GO:0016538
- GO:0030332
- GO:0106310
Related records
Trials (796)
- "Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "
- (CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer
- (VELA) Study of BLU-222 in Advanced Solid Tumors
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
- [18F]FLT PET/CT in Rb+ Metastatic Breast Cancer
- 7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors
- 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
- 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
- 7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer
- A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.
- A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer
- A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy
- A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
- A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.
- A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
- A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
- A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
- A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential.
- A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
- A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer
Drugs (18)
- Abemaciclib Cyclin-dependent kinase 4 inhibitor
- AG-24322 Cyclin-dependent kinase 4 inhibitor
- Alvocidib Cyclin-dependent kinase 4 inhibitor
- AT-7519 Cyclin-dependent kinase inhibitor
- AZD-5438 Cyclin-dependent kinase inhibitor
- Milciclib Cyclin-dependent kinase 4 inhibitor
- Palbociclib Cyclin-dependent kinase 4/cyclin D1 inhibitor
- PHA-793887 Cyclin-dependent kinase inhibitor
- RG-547 Cyclin-dependent kinase 4 inhibitor
- RGB-286638 Cyclin-dependent kinase 4 inhibitor
- Ribociclib Cyclin-dependent kinase 4 inhibitor
- Ribociclib succinate Cyclin-dependent kinase 4 inhibitor
- Riviciclib Cyclin-dependent kinase 4 inhibitor
- Roniciclib Cyclin-dependent kinase inhibitor
- Trilaciclib Cyclin-dependent kinase 4 inhibitor
- Trilaciclib dihydrochloride Cyclin-dependent kinase 4 inhibitor
- UCN-01 Cyclin-dependent kinase 4 inhibitor
- Voruciclib Cyclin-dependent kinase 4 inhibitor